Skip to main content
. 2021 Jun 18;44(6):1433–1442. doi: 10.2337/dc20-2151

Figure 4.

Figure 4

Percent change in secondary end points from baseline to week 54. A: Levels of total cholesterol. B: Levels of LDL cholesterol (LDLC). C: Levels of HDL cholesterol (HDLC). D: Levels of non-HDL cholesterol. E: Levels of triglycerides. *Vs. placebo. †Vs. liraglutide. Data are per-protocol population and are presented as LS means (95% CI).